Floatz logo

Etigilimab

Metastatic Solid Tumor

Mereo BioPharmaPhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

132 Active assets in the Metastatic Solid Tumor cohort.

Asset / SponsorPhaseRating
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2CCC
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2CCC
Epirubicin
InSilico Medicine Hong Kong Limited
Phase 2CCC
Nivolumab
Lantern Pharma Inc.
Phase 2CCC
Trastuzumab Emtansine
M.D. Anderson Cancer Center
Phase 2CCC

View all 50 →

Same molecule, other indications

Etigilimab is also rated in:

ovarian cancerDormant
CC
Indicative ·
46 / 100
View asset →
Solid Tumor, AdultDormant
CC
Indicative ·
44 / 100
View asset →
cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →